Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report

On May 10, Morgan Stanley lowered its terms proposal connected Gilead Sciences, Inc. (NASDAQ:GILD) to $168 from $175. It reiterated an Overweight standing connected the shares. The steadfast updated its exemplary for the institution pursuing the first-quarter net report.

On May 8, Truist lifted its terms extremity connected GILD to $157 from $155. It kept a Buy standing connected the stock. The expert said the institution delivered first-quarter gross and net results supra expectations and besides raised its FY26 gross guidance. According to the probe note, the show was driven by spot successful the HIV business, particularly Yeztugo. The steadfast besides highlighted management’s comments astir aboriginal persistence signals. It noted that Yeztugo showed the highest persistence among patients receiving re-treatment successful the PrEP setting. Truist described those trends arsenic encouraging and said they stay cardinal to its presumption that Yeztugo tin execute durable maturation toward a imaginable $7B-plus highest gross opportunity.

Gilead Sciences, Inc. (NASDAQ:GILD) is simply a biopharmaceutical institution focused connected processing medicines to forestall and dainty life-threatening diseases. Its areas of absorption see HIV, viral hepatitis, COVID-19, cancer, and inflammation.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 11 Best Dividend Penny Stocks to Buy Right Now and 11 Best Long Term US Stocks to Buy Right Now

Disclosure: None. Follow Insider Monkey connected Google News.